Cullinan Therapeutics, Inc.
Ticker: CGEM
| Insider | Title |
|---|---|
| Anne-marie Martin | Director |
| Ansbert Gadicke | Director |
| Anthony Rosenberg | Director |
| Bioscience I 2017 Ltd F2 | 10% or greater ownership |
| Capital Llc Bioimpact | 10% or greater ownership |
| Corrine Savill | Chief Business Officer |
| David D. Meek | Director |
| David P. Ryan | Director |
| Gp Holdings Llc Bvf | 10% or greater ownership |
| I Gp Llc Bvf | See Explanation of Responses |
| Ii Gp Llc Bvf | See Explanation of Responses |
| Impact Fund (cayman) Management L.p. Oncology | 10% or greater ownership |
| Inc/il Bvf | 10% or greater ownership |
| Jacquelyn L Sumer | Chief Legal Officer |
| Jeffrey Alan Jones | Chief Medical Officer |
| Jeffrey Trigilio | Chief Financial Officer |
| Jennifer Michaelson | Chief Scientific Officer |
| Leigh Zawel | See Remarks |
| Mark N Lampert | 10% or greater ownership |
| Mary Kay Fenton | Chief Financial Officer |
| Mary Thistle | Director |
| Morana Jovan-embiricos | 10% or greater ownership |
| Nadim Ahmed | President and CEO, Director |
| Nate Nguyen | Interim PAO and PFO |
| Oncology Impact Fund L.p. Ubs | 10% or greater ownership |
| Oncology Impact Management Gp Llc Mpm | 10% or greater ownership |
| Partners L P/il Bvf | 10% or greater ownership |
| Partners Os Ltd. Bvf | See Explanation of Responses |
| Patrick Baeuerle | Chief Scientific Officer |
| Raymond T Keane | Chief Legal Officer |
| Stephen W Webster | Director |
| Thomas Ebeling | Director |
| Value Fund Ii Lp Biotechnology | See Explanation of Responses |
| Value Fund L P Biotechnology | See Explanation of Responses |
| Value Trading Fund Os Lp Biotechnology | See Explanation of Responses |
| Vision Scs F2 | 10% or greater ownership |